The reactor, dubbed JT-60SA, represents the latest testbed for a potentially transformative source of renewable energy harvested from atoms fusing together under immense pressure and incredibly high temperatures — without risking a nuclear meltdown.
In the first trial, at the Peter MacCallum Cancer Center in Australia, CRC patients receiving just divarasib had a 35.9% positive response rate, which was considered extremely promising.
After only two doses, nearly eight out of ten participants in a phase 2 trial by Toronto-based pharmaceutical company Cybin experienced remission from major depressive disorder at six weeks. The company has a planned phase 3 study slated to commence by the end of Q1 2024.
SAF is designed to cut aviation carbon emissions by using sources that rely much less on fossil fuels: include maize, seed oils, algae, animal fats, oils, greases, farm residues, and more. According to Gulfstream, SAF has the potential to reduce net carbon emissions by 70%.
Northwestern University’s Prison Education Program has now welcomed its inaugural graduating class of incarcerated students. Around 100 students are enrolled in the Northwestern program across Stateville Correctional Center for men and the Logan Correctional Center for women.
Besides the eyeball, the patient, 46-year-old Aaron James of Hot Springs, Arkansas, also received a partial face transplant and an infusion of donor stem cells to the optic nerve during the more than 20-hour surgery.
Researchers from the Cleveland Clinic have conducted the first human trials of a new drug, lepodisiran, that has the potential to eliminate a risk factor for cardiovascular disease for which there is currently no treatment.
The new program aims to help students of color, first-generation college students and students from low-income households receive a higher education. After earning an associate degree, the new program will also allow students to receive a bachelor’s degree from the university for about $10,000.
The scientists from Shanghai’s Fudan University implanted new genetic code into a harmless virus and then injected the viruses into the children’s cochlea. They say the experiment has sparked hearing in four out of five children who received the treatment.
Dubbed “Calixcoca,” the treatment, developed by researchers at the Federal University of Minas Gerais, triggers an immune response that blocks cocaine and crack from reaching the brain. Last week, the project won the top prize of €500,000 at the Euro Health Innovation Awards for Latin American medicine.
